TY - JOUR
T1 - Adverse events associated with trimethoprim-sulfamethoxazole and atovaquone during the treatment of aids-related pneumocystis carinii pneumonia
AU - Hughes, Walter T.
AU - Lafon, Stephen W.
AU - Scott, Janna D.
AU - Grusby, Michael J.
AU - Masur, Henry
PY - 1995/5
Y1 - 1995/5
N2 - Atovaquone was compared to trimethoprim-sulfamethoxazole (TMP-SMZ) for the relationship of time receiving therapy, plasma drug concentrations, and incidence of adverse reactions in patients with AIDS-associated Pneumocystis carinii pneumonia. Treatment-limiting adverse events occurred in 9% of atovaquone-treated patients and 24% of TMP-SMZ-treated patients. Adverse events usually did not occur before day 7 for either treatment. Only the incidence of rash increased with increasing plasma concentrations of atovaquone. The incidence of anemia, neutropenia, and azotemia increased with increasing trimethoprim plasma concentration, while other adverse events (gastrointestinal disorders, rash, fever, and liver function abnormalities) were independent of plasma drug concentration.
AB - Atovaquone was compared to trimethoprim-sulfamethoxazole (TMP-SMZ) for the relationship of time receiving therapy, plasma drug concentrations, and incidence of adverse reactions in patients with AIDS-associated Pneumocystis carinii pneumonia. Treatment-limiting adverse events occurred in 9% of atovaquone-treated patients and 24% of TMP-SMZ-treated patients. Adverse events usually did not occur before day 7 for either treatment. Only the incidence of rash increased with increasing plasma concentrations of atovaquone. The incidence of anemia, neutropenia, and azotemia increased with increasing trimethoprim plasma concentration, while other adverse events (gastrointestinal disorders, rash, fever, and liver function abnormalities) were independent of plasma drug concentration.
UR - http://www.scopus.com/inward/record.url?scp=0028957202&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028957202&partnerID=8YFLogxK
U2 - 10.1093/infdis/171.5.1295
DO - 10.1093/infdis/171.5.1295
M3 - Article
C2 - 7751706
AN - SCOPUS:0028957202
SN - 0022-1899
VL - 171
SP - 1295
EP - 1301
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 5
ER -